Skip to main content
Premium Trial:

Request an Annual Quote

TrimGen Expects FDA Clearance of Warfarin Genotyping Test Soon

This article has been updated from a previous version to clarify statements from a TrimGen official about the company's expectations regarding FDA approval for its test. The company said that it has not yet received official notification from the FDA, and that it expects the test to clear in the near future, rather than by the end of the month, as the firm previously stated. 
NEW YORK (GenomeWeb News) - TrimGen expects the US Food and Drug Administration to clear as an in vitro diagnostic its warfarin-dosing test “in the near future,” James Doherty, TrimGen product specialist, told GenomeWeb Daily News sister publication Pharmacogenomics Reporter this week.
Maryland-based TrimGen, which submitted its 510(k) application for the eQ-PCR LightCycler Warfarin Genotyping Kit in December 2007, said it plans to differentiate its test from rivals’ products based on its 1.5-hour turnaround and relative ease of use.
TrimGen has looked at the clinical and analytical validity of the test in a 170-patient study at three sites. Doherty said the diagnostic, which is based on Roche's eq-PCR LightCycler platform, had 100 percent agreement with bi-directional sequencing.
TrimGen also markets the Mutector II Warfarin Genotyping Test kit, a homebrew that analyzes samples using an Applied Biosystems capillary sequencer.
If cleared, the company’s LightCycler warfarin test will be the fifth such product to win regulatory approval in the US behind those made by ParagonDx, AutoGenomics, Nanosphere, and Osmetech. There are also several homebrew assays marketed by Laboratory Corporation of America, Idaho Technology, and Clinical Data, among others.
TrimGen’s test is designed to detect what are generally believed to be the most clinically relevant genetic variations responsible for patient sensitivity to the anticoagulant: the CYP 2C9*2 (C430T), 2C9*3 (A1075C), and VKORC1 (-1639 G>A) mutations.
However, there are several competing products on the market that offer testing for other mutations. For instance, Genelex’s homebrew Warfarin Target Dose Safety Test, based on Luminex Molecular Diagnostics’ Tag-It Universal Array platform, gauges CYP 2C9 *2, *3, *4, *5, *6, and VKORC1 (-1639 G>A) mutations. Nanosphere’s FDA-approved Warfarin Metabolism Nucleic Acid Test gauges CYP 2C9 *2, *3, as well as VKORC1 (-1639 G>A) and (1173C>T).
Meanwhile, AutoGenomics boasts that its INFINITI assay detects 15 2C9 and VKORC1 variants, more than any other company in the market. Among the 15 variants the Infiniti assay detects, several polymorphisms will be specific to particular ethnicities – such as the *4 variant identified exclusively among Japanese people and the 8,773 SNPs in VKORC1 found in 21 percent of African Americans.

A more comprehensive version of this article appears in this week's issue of Pharmacogenomics Reporter.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.